Pharmacokinetic and Pharmacodynamic Profiles of Ethinylestradiol/Norgestimate Combination or Norethindrone upon Coadministration with Elagolix 150 mg Once Daily in Healthy Premenopausal Women

BACKGROUND: Two pharmacokinetic/pharmacodynamic studies were conducted to evaluate the potential drug–drug interaction between elagolix, an oral gonadotropin-releasing hormone receptor antagonist, and an oral contraceptive (ethinylestradiol [EE] 0.035 mg and norgestimate 0.18/0.215/0.25 mg) or proge...

Descripción completa

Detalles Bibliográficos
Autores principales: Feldman, Robert A., Chiu, Yi-Lin, Klein, Cheri E., Ng, Juki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8332571/
https://www.ncbi.nlm.nih.gov/pubmed/33748934
http://dx.doi.org/10.1007/s40262-021-00989-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8332571/
https://www.ncbi.nlm.nih.gov/pubmed/33748934
http://dx.doi.org/10.1007/s40262-021-00989-0

Ejemplares similares